Dallas, Texas · May 12, 2026
Innovate. Prove. Realize.

A purpose-built commercial organization for surgeon-developed medical device IP. From patent to operating room to strategic exit — without the surgeon ever having to become a business operator.

Scroll to explore
The Problem We Solve

Surgeons innovate.
The system fails them.

"The surgeon entrepreneur has the idea, the IP, and the clinical proof. What they lack is the time, the commercial infrastructure, and the right team to turn that into lasting value."
  • Large OEMs lowball acquisition offers because the surgeon has no commercial leverage and no utilization data to negotiate with.
  • The proving phase — getting the product into real cases with real surgeons — requires a commercial organization most inventors don't have.
  • 510(k) pathways, manufacturing sourcing, and distribution networks are full-time jobs that surgeons cannot run in parallel with a clinical practice.
  • Without a proven revenue track record, IP sells for a fraction of its actual market value.
  • The window to act is narrow. Maintenance deadlines, competitive products, and market timing don't wait.
What LoxaNova Does

We run the commercial engine.
You own the outcome.

LoxaNova is a self-contained domestic commercial organization built specifically for surgeon IP. We take a product from patent to operating room to acquisition-ready — and the surgeon retains ownership through every stage.

01
Innovate
Protect & Prepare

IP audit, maintenance management, 510(k) pathway mapping, and manufacturing sourcing. We handle the infrastructure that turns a patent into a market-ready product.

02
Prove
Build the Record

Proof-of-concept deployment in a controlled Texas market. Trained field educators in the OR. Every case documented. Every procedure tied to a patent family. Clean utilization data that supports a premium valuation.

03
Realize
Exit on Your Terms

Individual IP brokerage or full company acquisition. We bring the utilization data, the commercial track record, and the competitive tension that creates real negotiating leverage with strategic buyers.

Suremka LLC — The Foundation

Thirteen patents.
One focused thesis.

Every arthroscopic procedure uses a cannula. Dr. Worrel's Suremka portfolio owns a meaningful piece of that space — surgical access and instrumentation technology developed over a decade of high-volume clinical practice at the Carrell Clinic and in the NBA. The portfolio is clean. No existing licenses. No encumbrances. Ready to move.

9
Issued US patents covering surgical access and instrumentation
1
European patent active in UK, France, and Germany
4
Pending applications including newest filed June 2025
Patent Description Year Status
8,777,902 Retractable Cannula — Generation 1 2014 Issued
10,258,368 Retractable Cannula — Generation 2 2019 Issued
EP15806528.4 Retractable Cannula — UK, France, Germany 2020 European
10,342,577 Surgical Devices and Methods 2019 Issued
10,687,846 Surgical Devices and Methods — Divisional 2020 Issued
11,607,246 Surgical Device Deployment Apparatuses 2023 Issued
11,607,322 Graft Compression System 2023 Issued
12,427,039 Graft Compression System — CIP 2025 Issued
11,627,985 Surgical Devices & Deployment Apparatuses 2023 Issued
18/355,936 Surgical Devices & Deployment Apparatuses Pending Pending
18/336,287 Knotless Suture Shuttling & Anchoring System Pending Pending
18/295,414 Surgical Devices & Deployment Apparatuses Pending Pending
19/252,607 Surgical Devices & Deployment Apparatuses — Newest 2025 Pending
What This Means For You

Mailbox money.
On your terms.

The goal is simple. Daniel focuses on patients. LoxaNova runs the commercial organization, builds the data record, and creates the conditions for a premium exit. The surgeon entrepreneur finally has a partner who knows how to execute.

I.
No Operational Burden

You don't manage reps, chase purchase orders, or sit in VAT committee meetings. LoxaNova handles the entire commercial layer. Your time stays in the OR.

II.
Real Utilization Data

Every case documented. Every procedure tied to your IP. When a strategic buyer asks for proof of market adoption, we hand them a clean report instead of a pitch deck.

III.
Negotiating Leverage

A proven commercial track record changes the acquisition conversation. You stop being a seller with an idea and become a seller with a business. That distinction is worth multiples.

IV.
A Bigger Vision

This is the first chapter. LoxaNova becomes the platform other surgeon entrepreneurs use to bring their IP to market. Your success builds something that helps the entire community of surgical innovators.

May 12, 2026 · Dallas

This is the conversation
worth having.

No term sheets today. No legal discussions. Just three people who have built real things in this industry sitting down to talk about whether this is worth doing together. We believe it is.

LoxaNova · Innovate. Prove. Realize.